Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



The Obesity-Drug Wars Officially Begin

It's a day that Arena Pharmaceuticals investors have long, long waited for: Obesity drug Belviq is now on the market. 

The company had a seemingly endless wait for DEA scheduling, ultimately receiving class 4 status. In the meantime, competitor VIVUS got its obesity drug Qsymia approved and into patients' hands. 

In this video, health-care analyst David Williamson checks in on the obesity-drug wars, where things stand between Arena and VIVUS, and what Arena investors should look out for given some of Qsymia's initial challenges.

Who will win the obesity drug market?
Can VIVUS pick up its lagging sales and fend off the competition, or will Arena Pharmaceuticals reign supreme in the obesity space? If you're in the dark, grab copies of The Motley Fool's premium research reports on VIVUS and Arena Pharmaceuticals to stay up to date. Senior biotech analyst Brian Orelli gives investors the must-know information, including an in-depth look at the obesity market and reasons to buy and sell both stocks. Click now for an exclusive look at Arena and VIVUS -- complete with a full year of free updates -- today.

Read/Post Comments (3) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 11, 2013, at 10:54 PM, keahou wrote:

    My MD friends say that they would never prescribe Qysmia, a combo of 2 generics which have been available for decades. It is cheaper to just take these generics which haven't done much either, so how can Qysmia be successful? Also, this efficacy chatter is erroneous. Twice the normal dose of Qysmia is trumpeted by all articles as the standard but that only applies to a minority of patients. When you use the recommended dose of Qysmia it has the same efficacy as Belviq. So this race will be a non event. Qysmia's scripts actually dropped last week.

  • Report this Comment On June 12, 2013, at 8:09 AM, csmstreeter wrote:

    Another pill? Easier less, move more!

  • Report this Comment On June 12, 2013, at 8:39 AM, adumfraudstain wrote:

    There will be no US market obesity 'war'. Reformulated generic combo Qsymia is already on life support and will be a no show.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2484378, ~/Articles/ArticleHandler.aspx, 8/27/2016 2:53:52 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 5 hours ago Sponsored by:
DOW 18,395.40 -53.01 -0.29%
S&P 500 2,169.04 -3.43 -0.16%
NASD 5,218.92 6.71 0.13%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/26/2016 4:00 PM
ARNA $1.63 Down +0.00 +0.00%
Arena Pharmaceutic… CAPS Rating: **
VVUS $1.06 Up +0.02 +1.92%
VIVUS CAPS Rating: **